Abstract:
:Coronary arterial thrombolysis is becoming an established treatment of acute myocardial infarction. If given early enough, it recanalises occluded coronary arteries, salvages myocardial function and reduces mortality. A reduction of mortality in patients with acute myocardial infarction has now been demonstrated for streptokinase, anisoylated plasminogen streptokinase activator complex (APSAC; anistreplase) and recombinant tissue-type plasminogen activator (rt-PA). From the biochemical point of view, rt-PA has several attractive properties. It is similar to or identical with the physiological plasminogen activator in blood, it does not induce an antibody response, and it is more fibrin-specific than most or all other currently known thrombolytic agents. The rate of recanalisation of occluded coronary arteries with rt-PA is about 60 to 80% in non-comparative and placebo-controlled trials. rt-PA was similar in efficacy to urokinase in the only trial to compare the 2 agents. In 2 comparative trials evaluated by meta-analysis, rt-PA appeared more effective than streptokinase for the early recanalisation of occluded arteries. Both agents were comparable in their effects on left ventricular function in 2 comparative trials, but further study is needed to conclusively evaluate this parameter. Moreover, both agents reduce inhospital mortality, but much larger direct comparative trials are required before scientifically valid statements can be made on the relative clinical efficacy of available thrombolytic agents in terms of their effects on both morbidity and mortality. Thus, rt-PA constitutes a notable contribution of recombinant DNA technology to the treatment of thromboembolic disease, the main cause of death and disability in Western societies.
journal_name
Drugsjournal_title
Drugsauthors
Collen D,Lijnen HR,Todd PA,Goa KLdoi
10.2165/00003495-198938030-00003subject
Has Abstractpub_date
1989-09-01 00:00:00pages
346-88issue
3eissn
0012-6667issn
1179-1950journal_volume
38pub_type
杂志文章,评审相关文献
DRUGS文献大全abstract::In the table 'Key clinical trials of isatuximab (Sanofi)', in the left-hand column. ...
journal_title:Drugs
pub_type: 杂志文章,已发布勘误
doi:10.1007/s40265-020-01325-9
更新日期:2020-06-01 00:00:00
abstract::Sulbactam is a semisynthetic beta-lactamase inhibitor which when combined with certain beta-lactam antibacterials extends their activity against bacteria that are normally resistant to the antibiotic due to production of beta-lactamases. In combination with ampicillin it extends the antibacterial activity of ampicilli...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198733060-00003
更新日期:1987-06-01 00:00:00
abstract::Cenobamate (XCOPRI®) is an oral, small molecule neurotherapeutic azole compound that is being developed by SK Life Science Inc. and Arvelle Therapeutics for the treatment of epilepsy. Based on results of two pivotal phase 2 trials, cenobamate was recently approved in the USA for use in the treatment of partial-onset s...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01250-6
更新日期:2020-01-01 00:00:00
abstract::The phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway is implicated in the pathogenesis of lymphoma. Deeper understanding of the diversity and biological impact of this pathway has led to the development of specific inhibitors to this pathway. Preclinical data in cell lines, patient samples and disease models have bro...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-016-0565-4
更新日期:2016-04-01 00:00:00
abstract::There are several first choices for the treatment of mild and moderate hypertension. The selection of a drug may be influenced by concomitant pathology, with positive indications for particular drugs, e.g. coexistent angina, indicating use of a beta-receptor blocking drug or calcium antagonist; fluid retention indicat...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198800356-00006
更新日期:1988-01-01 00:00:00
abstract::Gastric cancer is the seventh and oesophageal cancer the ninth most common cancer in the UK, and >50% of patients present with locally advanced or metastatic disease. The incidence of oesophageal and oesophagogastric junctional tumours is increasing, making these important disease entities to understand and research. ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200767170-00006
更新日期:2007-01-01 00:00:00
abstract::Prostaglandin E2 (PGE2) is a potent stimulator of inflammation, and the inhibition of its synthesis is one possible mechanism of action of non-steroidal anti-inflammatory drugs (NSAIDs). We have investigated patients suffering from rheumatoid arthritis to determine how synovial fluid levels of PGE2 are affected by tia...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-198800351-00004
更新日期:1988-01-01 00:00:00
abstract::Nizatidine is an H2-receptor antagonist which in animal studies was more active on a weight-for-weight basis than cimetidine in inhibiting basal and stimulated gastric acid secretion. Similarly, studies in humans have confirmed that nizatidine is a potent inhibitor of basal, nocturnal and stimulated gastric acid secre...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198836050-00002
更新日期:1988-11-01 00:00:00
abstract::Diabetic gastroparesis is a common and debilitating condition affecting millions of patients with diabetes mellitus worldwide. Although gastroparesis in diabetes has been known clinically for more than 50 years, treatment options remain very limited. Until recently, the scientific literature has offered few clues rega...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200363130-00002
更新日期:2003-01-01 00:00:00
abstract::Antiviral therapy has in the past met with limited success and only a few antiviral drugs have been available. The human immunodeficiency virus (HIV) epidemic has created an urgent need for the development of antiviral therapy against this infection. HIV replication offers several targets for inhibitory compounds, the...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199345040-00002
更新日期:1993-04-01 00:00:00
abstract::The binding of drugs to proteins is an important pharmacokinetic parameter. Many methods are available for the study of drug protein binding phenomena and there are also many ways to interpret the binding data. Although much emphasis has been placed on the binding of drugs in the plasma, binding also takes place in th...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198325050-00003
更新日期:1983-05-01 00:00:00
abstract::Drotrecogin alfa (activated), recombinant human activated protein C, inhibits coagulation and inflammation and promotes fibrinolysis in patients with severe sepsis. 850 patients with severe sepsis treated with intravenous drotrecogin alfa (activated) 24 microg/kg/h for 96 hours had a significantly greater reduction in...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-200262040-00006
更新日期:2002-01-01 00:00:00
abstract::Pancreatic islet transplantation as a cell-based treatment for diabetes mellitus has been pursued for over quarter of a century, ever since the first successful use of this approach to cure diabetes mellitus in rodents in the 1970s. However, even though autoislet intrahepatic transplantation in patients with chronic p...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-200161140-00001
更新日期:2001-01-01 00:00:00
abstract::After surgery, patients try to minimise discomfort by various manoeuvres including change of posture, immobilisation of injured areas and use of analgesic drugs. The characteristic finding with drug use, revealed by permitting patients to titrate themselves with analgesic from a machine, is that the interindividual do...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198529040-00004
更新日期:1985-04-01 00:00:00
abstract::Arrhythmia treatment has always been difficult, particularly as there are no good indicators of the optimal management strategy. The introduction of new antiarrhythmic agents has forced reappraisal of how these drugs are used. Dynamic electrocardiography and invasive electrophysiological studies are important tools fo...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198836050-00005
更新日期:1988-11-01 00:00:00
abstract::Exenatide extended-release (exenatide ER) [Bydureon(®)] is a glucagon-like peptide-1 receptor agonist, approved for the treatment of type 2 diabetes mellitus. It is injected subcutaneously by patients once weekly, with no dose titration required. This article updates an earlier review of exenatide ER in the management...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-015-0420-z
更新日期:2015-07-01 00:00:00
abstract::Stavudine is a nucleoside analogue which undergoes intracellular phosphorylation to its active metabolite, stavudine-5'-triphosphate. At clinically relevant concentrations, the active metabolite restricts HIV replication by inhibiting the inclusion of thymidine-5'-triphosphate into proviral DNA by HIV reverse transcri...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199651050-00009
更新日期:1996-05-01 00:00:00
abstract::Eplerenone (Inspra) is a selective aldosterone blocker. Oral eplerenone is approved for use in patients with left ventricular (LV) systolic dysfunction and clinical evidence of heart failure following acute myocardial infarction (MI) in the US and in European countries (e.g. the UK and The Netherlands). The addition o...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200464230-00005
更新日期:2004-01-01 00:00:00
abstract::Aripiprazole (Abilify®) is an atypical antipsychotic indicated for the treatment of mania associated with bipolar I disorder. It is unique in its class, as it is a partial agonist of dopamine D(2) and D(3), and serotonin 5-HT(1A) receptors and a modest antagonist of 5-HT(2A) receptors. This article reviews the pharmac...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11208320-000000000-00000
更新日期:2012-01-01 00:00:00
abstract::Irinotecan (CPT-II) is a semisynthetic derivative of camptothecin. It and other camptothecin analogues/derivatives appear to exert their antitumour activity by binding to topoisomerase I. The active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), has demonstrated potent growth inhibition of human col...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199652040-00013
更新日期:1996-10-01 00:00:00
abstract::The hyperkinetic syndrome is a symptom complex of hyperactivity, short attention span, distractibility, impulsivity, learning difficulties, other behaviour problems and 'equivocal' neurological signs. However, none of these terms has ever been objectively defined and at present diagnosis is largely a matter of clinica...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-197611020-00001
更新日期:1976-01-01 00:00:00
abstract::Mantle cell lymphoma is a rare yet well defined subtype of B-cell non-Hodgkin's lymphoma. The correct histological diagnosis of this lymphoma subtype is of the utmost importance; however, it is also a very difficult diagnosis. Clinical management is often complex, and despite the successful introduction of monoclonal ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200767120-00004
更新日期:2007-01-01 00:00:00
abstract::HMG-CoA reductase inhibitors (statins) have been shown to reduce mortality and cardiovascular morbidity in patients with hyperlipidaemia and those with coronary artery disease. However, evidence for statin treatment in patients with chronic heart failure (CHF) remains a subject of debate. Patients with heart failure w...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666020-00002
更新日期:2006-01-01 00:00:00
abstract::Lifestyle interventions constitute the initial strategy for the primary and secondary prevention of cardiovascular disease in women. However, pharmacotherapy is often indicated for control of major cardiovascular risk factors, and abundant clinical trial data support the morbidity and mortality benefit of a number of ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200868030-00006
更新日期:2008-01-01 00:00:00
abstract::Safety data have been gathered in US clinical trials of nabumetone on 1912 patients from August 1981 to May 1988. Dosing in the double-blind trials was 100 mg at bedtime, but in open-label trials patients could increase the dosage of nabumetone to 1500 or 2000 mg if required. Adverse experiences reported in the double...
journal_title:Drugs
pub_type: 临床试验,杂志文章
doi:10.2165/00003495-199000405-00008
更新日期:1990-01-01 00:00:00
abstract::The occurrence of late side effects of long term levodopa therapy (fluctuations in motor performance, abnormal movements, and symptoms unresponsive to dihydroxyphenylalanine) led to the search for novel anti-Parkinsonian drugs. Dopamine agonists are one of the newer families of anti-Parkinsonian agents, and they inclu...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199346030-00005
更新日期:1993-09-01 00:00:00
abstract::Resistance to the metabolic actions of insulin is thought to play a determining role in the aetiology of a great variety of disorders, including essential hypertension, accelerated atherosclerosis and cardiomyopathies. ACE inhibitors are recognised as being highly effective therapy for hypertension and cardiac insuffi...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200262090-00002
更新日期:2002-01-01 00:00:00
abstract::Roxatidine acetate (HOE 760, TZU 0460) is a new H2-receptor antagonist which is more potent than cimetidine and ranitidine. A randomised, double-blind, placebo-controlled study was conducted in healthy men to determine the effects of multiple oral doses of roxatidine acetate on unstimulated gastric acid secretion, and...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-198800353-00011
更新日期:1988-01-01 00:00:00
abstract::Novo Nordisk has developed a subcutaneous formulation of semaglutide (Ozempic®), a modified human glucagon-like peptide-1 (GLP-1) analogue, for the treatment of type 2 diabetes mellitus. It has been developed using Novo Nordisk's proprietary protein-acylation technology, and is administered using an injection device. ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-018-0871-0
更新日期:2018-02-01 00:00:00
abstract::Estrogenic compounds are the most important group of drugs that can induce hypertension. Studies have shown an incidence of significant hypertension amounting to less than 1% after 1 year of taking oral contraceptives and about 2% after 5 years. The ratio of the incidence of hypertension among ''takers'' to that of ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-197612030-00005
更新日期:1976-01-01 00:00:00